Kexing Biopharm Logo.jpg
Led by Sci-tech Innovation, Expanding into Global Markets - Kexing Biopharm in International Exhibitions
10 mai 2023 09h15 HE | Kexing Biopharm
Shenzhen, China, May 10, 2023 (GLOBE NEWSWIRE) -- As internationalization gradually becomes the mainstream trend of development for China's biopharmaceutical industry, enterprises have intensified...
Cingulate_Logo_400x400_twitter.jpg
Cingulate to Present at LD Micro Investor Conference
20 oct. 2022 14h20 HE | Cingulate Inc.
KANSAS CITY, Kan., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
GME_18x18.jpg
Global Biopharmaceutical Stability Testing Market Size
04 août 2022 09h00 HE | Global Market Estimates
Brooklyn, New York, Aug. 04, 2022 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Global Biopharmaceutical Stability Testing Market is...
Cingulate_Logo_400x400_twitter.jpg
Cingulate to Present at H.C. Wainwright Global Investment Conference
18 mai 2022 17h20 HE | Cingulate Inc.
KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Fibrocor, a MaRS Inn
Fibrocor, a MaRS Innovation portfolio company, announces deal with Galapagos
07 janv. 2019 10h43 HE | MaRS Innovation
Toronto, ON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fibrocor Therapeutics, a privately held Canadian company, and Galapagos NV, a Belgo-Dutch pharmaceutical research company, have announced the formation...